Statins are one of the most potent drugs in delaying age -related inflammatory changes in the arterial vessel wall, slowing down the progression of atherosclerosis.
Introduction
Telomerase is a ribonucleoprotein composed of an RNA subunit (TERC), serving as a template for telomere repeat addition, and a reverse transcriptase (TERT) subunit that facilitates the replication of telomeres, the ends of chromososmes [1, 2] . TERT also has additional functions beyond telomere maintenance . These include the control of gene expression, chromatin organisation and mitochondr ia shuttling [3] [4] [5] .
Multiple studies so far have provided evidence for an association of short telomeres with conditions of increased oxidative stress, including smoking, obesity and coronary heart disease (CHD) [6] [7] [8] [9] [10] [11] . In a cohort of 1500 patients the WOSCOPS substudy identified that the telomere-attributed risk of developing coronary heart disease was attenuated by treatment with pravastatin [12] . Atorvastatin has been demonstrated to reduce oxidative stress in various clinical studies, including patients with atherosclerosis, hypercholesterolemia, rheumathoid arthrits, chronic kidney disease and polycystic ovarian syndrome [13] [14] [15] [16] [17] [18] . However, it remains unclear whether short telomere length is only a bystander in atherosclerosis and whether statins can exert a direct effect on telomere length. We previously published that telomere length shortening in CHD patients, when compared to age -matched controls, is more pronounced in T-lymphocytes (T cells) than in myeloid cells, suggesting that T cells could play an important role in ageing -and telomeremediated atherogenesis [19] . T cell mediated immune responses play important roles at all stages of atherosclerotic lesion development [20] with the majority of T cells in an atherosclerotic lesion being CD4+ T-helper cells (Th1) that produce interferon- [21] [22] [23] .
In vitro, atorvastatin has been shown to inhibit T cell activation and proliferation, thereby exerting an anti-inflammatory effect [24, 25] . However, these and similar studies used drug concentrations of up to 10 M, 30 times higher than in the plasma of atorvastatin-treated patients [26] . In pharmacologically relevant dosages, statins have been shown to induce the Akt pathway and promote proliferation in endothelial cells [27] . We have also shown that statins induce telomere-repeat binding factor TRF2 in endothelial progenitor cells [28] . Telomere length was found to be longer in patients under statin therapy compared to those without [29] . A recent study of 230 subjects showed that statin therapy was associated with higher telomerase activity independently of multiple covariates, including age, gender, cardiovascular risk factors and systemic inflammation [30] . In the same study, subjects on statin treatment also showed significant lower telomere erosion along with aging. The goal of our study was to investigate the in-vitro effect of atorvastatin on telomerase and the mechanistic relation between proliferation and telomerase in this context.
Methods

T-cell receptor ligation and culture of human PBMCs
Human peripheral blood mononuclear cells (PBMCs) were isolated by Ficoll-hypaque density gradient (using Biochrom AG Biocoll L 6113/5) and prepared at 5x10 6 /ml in supplemented RPMI 1640. For T-cell activation, 24 well plates (VQR 734-2325) were coated overnight with anti-CD3 (BD 550367) and anti-CD28 (BD 555725) antibodies prepared at 1µl/ml PBS at 4°C, except for unstimulated controls. Cells were then cultured in RPMI 1640 (Gibco 21875-034) supplemented by 3mM L-glutamine, 10%
foetal bovine serum (PAA A15-151) and 30μg/ml of pen/strep (Gibco 15070-063).
Buffy coats were purchased from the National Blood Service, Newcastle Upon Tyne.
Ethical approval was granted by the Newcastle University faculty of medical sciences ethics committee, 000205/2009.
Animals
TERT (Jax strain B6.129S-Tert tm1Yjc/J) [31] and TERC (Jax strain B6.Cg-Terc tm1Rdp/J) [32] animals were purchased from Jackson Laboratory, Maine, USA.
mTert-GFP transgene reporter mice were previously described [33, 34] . To confirm the phenotype of GFP transgenic mice, blood from the mouse tail was taken and (BD 553238) and CD28 (BD 553295) antibodies prepared at 1µl/ml PBS at 4°C.
PBMCs were isolated by Ficoll-hypaque density gradient and prepared at 2x10 6 /ml in supplemented RPMI 1640.
Long-term culture and growth curves
Long-term culture of human PBMCs was prepared at 5x10 6 instructions. Individual wells were compiled after a total cell number of 25x10 6 was reached, the resultant aspirated pellet resuspended in 50ml complete mouse medium to achieve the required 2x10 6 /ml in 50ml flasks.
Hypoxia and normoxia culture conditions
Hypoxia (3%) and normoxia (atmospheric 20%) culture conditions were maintained throughout experiments in Heraeus Hera Cell 150 incubators. Conditions of 5% CO 2 and 37C were constant.
Pharmacological activators and inhibitors
Atorvastatin was kindly donated by Pfizer and prepared in dimethyl sulfoxide (DMSO, Sigma 472301) to working dilutions of 5µM, 2µM, 0.3µM, 0.1µM and 0.02µM.
Interleukin-2 (IL-2, R&D 202-IL) was prepared from frozen stocks (-20°C) of 100µg/ml and added in a working concentration of 1.5µg/ml. Ly294002 (Cell Signaling 9901) was prepared at working doses of 10µM, 2µM and 0.4µM in DMSO.
Akt kinase 1/2 inhibitor (Sigma A6730) was prepared at working doses of 10µM, 2µM
and 0.4µM in DMSO. For all experiments and conditions, DMSO concentrations in culture medium never exceeded 0.1% and 0.1% DMSO was added to control wells.
Addition of LDL cholesterol in cholesterol-free media
Human plasma LDL cholesterol (Sigma L7914) was diluted in 150 mM NaCl and 0.01% EDTA to working stocks of 200, 100 and 50mg/dl added to RPMI supplemented by 10% lipoprotein deficient serum (Sigma S5394) 30μg/ml of pen/strep (Gibco 15070-063). Cholesterol was added serially at each media change every 2-3 days.
Immunomagnetic sorting of human CD4 and CD8 T-cells
Single 
Telomere length (Flow-FISH)
Telomere length measurements were carried out as previously described [28, 35, 36] .
In brief, each sample, containing 100,000 bovine thymocytes as an internal standard and 200,000 cells from the patient, was resuspended in a hybridization mixture containing telomere-specific N-terminal FITC-conjugated (C 3 TA 2 ) 3 peptide nucleic acid probe, washed and counterstained with propidium iodide before analysing by FACS analysis.
Statistics
Significance between data was compared by one-way ANOVA followed by Tukey's post hoc analysis, or 2 way ANOVA followed by Bonferroni's post-hoc analysis.
P<0.05 was considered statistically significant.
Results
Atorvastatin induces telomerase at pharmacological dosages
PBMCs were isolated from healthy volunteers and co-stimulated with -CD3 and -CD28 in culture. The addition of atorvastatin lead to an 6-fold increase in telomerase activity, peaking at 0.3 M concentration after 5 days ( Figure 1A) . A time course study confirmed that telomerase activity (TA) was only temporarily induced and reached its maximum after 5 days, then receding back to baseline levels at day 10 ( Figure 1B) . Statins have been shown to exert some of their protective effects on vascular cells through the Akt/PI3 kinase pathway [27] . Induction of telomerase by atorvastatin was prevented by inhibitors of the Akt and PI3 kinase pathway, respectively ( Figures 1B and 1C ). To determine whether specific subsets of T cells
were affected by atorvastatin, we examined populations of purified human CD4 and CD8 T cells seperately. Here we found that induction of TA was most pro nounced in CD4 compared to CD8 T cells (650% vs 256%, Figure 1E ). Finally, we analysed mononuclear cells from patients with acute ST elevation myocardial infarction (STEMI), a state of high inflammation. We found TA in unstimulated PBMCs to be 5-fold reduced compared to controls (p<0.05 vs healthy controls, p<0.01 vs postinfarction; Figure 1F ).
The effect of atorvastatin on T-lymphocyte proliferation is dose-dependent
In order to test the effect of statins on T-cell proliferation, mononuclear cells from Akt-kinase inhibitor ( Figure 2E ).
LDL cholesterol suppresses telomerase
We next sought to investigate whether the statin effect on telomerase was codependent on cholesterol metabolism. For this we used cholesterol free media and added increasing concentrations of LDL cholesterol. At 100 mg/dl TA was completely suppressed and no statin effect visible ( Figure 3A ). To exclude that the reduction in telomerase activity was not an artificial result of the PCR-based assay, we performed growth curves in human ( Figure 3B ) and murine ( Figure 3C ) T-cells. For both species, LDL cholesterol significantly inhibited T cell proliferation.
Telomerase activation in lymphocytes declines with age
We have previously generated an mTert-GFP transgenic mouse model in which GFP expression indicates endogenous mTert expression and telomerase activity. mTert-GFP + cells among peripheral blood lymphocytes decreased from 30% to 15%
continuously between the 2nd and the 5th month (p<0.01, Figure 3D and 3E), suggesting a correlation of telomerase-positive lymphocytes with cell turnover invivo.
Telomerase me diates the proliferative effect of atorvastatin
Atorvastatin induced TA under 3% (p<0.001, Figure 4A ) and to a lesser degree under 20% ( Figure 4B ) oxygen in murine T cells. The linearity of the TRAP assay was confirmed for murine cells ( Figure 4C ). So far we have shown that the induction of TA is paralleled by a moderate increase in T cell proliferation. To prove a causal relationship, we isolated murine splenocytes with a genetic knockdown of TERT [31] , the catalytic subunit of telomerase, and monitored T cell proliferation over 4 weeks in culture. As expected, T cells from heterozygous TERT +/-mice already displayed reduced proliferation (p<0.05, Figure 4D ). Knock-out of TERT further reduced T cell growth over 4 weeks (p<0.0001 vs wild type, Figure 4D ). Atorvastatin only enhanced proliferation in TERT +/+ splenocytes with preserved telomerase activity at a dose of 0.3 M, but not in TERT -/-cells ( Figure 4E ). At the highest dose (5 M), atorvastatin completely inhibited 3 H-thymidine incorporation at later timepoints, independent of telomerase (data not shown).
To exclude the possibility that differences in proliferation were secondary to telomere length (TL) shortening in the telomerase-deficient animals, we measured mean telomere length of splenocytes. As expected, splenocytes from first generation (F1) mTert -/-mice did not reveal any TL shortening ( Figure 5A ), while heterozygous mTerc +/-mice already displayed shorter TL (p<0.001). Finally, we attempted to explain the role of telomerase for statin-induced T cell proliferation. The statininduced increase in proliferation was completely dependent on functional mTert ( Figure 5B ) with a residual effect in TERC -/-T cells ( Figure 5C ). Again, shorter TL in cells from second generation TERC mice (F2) had no impact on the statin effect ( Figure 5B and 5C).
Discussion
Statins are established as a first-line therapy for secondary prevention in patients with documented coronary heart disease, improving morbidity and mortality. While the preponderance of evidence strongly suggests that a lower serum concentration of LDL cholesterol is the principal mechanism responsible for impro ved outcome, the benefits of statin therapy, particularly in primary prevention, may extend beyond those attributable to lipid-lowering (termed pleiotropic effects) [37] . Taking Given the importance of T-lymphocytes in atherogenesis and our findings that in patients with CHD telomeres from peripheral blood lymphocytes shorten faster th an in myeloid cells, [19, 36] our data suggest that telomere length might be a downstream target in T cells. However, this does not exclude that critically short telomeres in subsets of human T cells will affect their proliferation by driving a senescent phenotype of these cells. Restoring telomerase activity in T-cells, e.g. through small molecule activators such as TA-65 [42, 43] , could prove to be a powerful therapeutic intervention in age-related diseases such as atherosclerosis. Future studies have to identify the cell-specific role of telomerase in atherogenesis. In the mouse model, this can be accomplished by studying cholesterol-fed Apo E null x mTert-GFP reporter mice. We could not find identify telomerase-independent functional differences in murine T cells. However, mouse telomeres are several-fold longer than human telomeres. In our opinion, decreased telomerase activity in human T cells might accelerate telomere shortening and cellular senescence over a long period of time.
Our unpublished data from the Newcastle 85+ study (Spyridopoulos et al., manuscript in preparation) suggests that immunosenescence can be an independent predictor of outcome in the elderly, possible via accelerated atherosclerosis.
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